by James Lyons-Weiler, Ph.D., Childrens Health Defense:
The Centers for Disease Control and Prevention’s vaccine advisory committee met Wednesday to mull over next steps for COVID-19 vaccines, suggesting the agency knows the vaccine program has failed.
TRUTH LIVES on at https://sgtreport.tv/
Some members of the Advisory Committee on Immunization Practices (ACIP) suggested “entirely different vaccine formulations could be needed.”
Currently, additional booster doses are recommended only for certain people with weakened immune systems and adults 50 and older.
The CDC quoted Dr. Sara Oliver, one of the agency’s epidemic intelligence service officers with the Division of Viral Diseases, who provided a robust soundbite:
“Policy around future doses requires continued evaluation of COVID-19 epidemiology and vaccine effectiveness, including the impact of both time and variants, and the ability of doses to improve this protection.”
CNN cited Oliver as saying the CDC needs to take into account recent case counts, hospitalization rates and vaccine effectiveness in the U.S., and also — shocking — whether the vaccines are waning over time.
Oliver also said she thought the CDC should weigh “the impacts of circulating coronavirus variants.”
We know vaccine effectiveness is unacceptably low — and given the findings of Jacques Fantini, a biochemist and professor of virology at Aix-Marseille Université in Marseille, France, the vaccines could have negative effectiveness, indicating disease enhancement.
Oliver said the evolution of the virus will be an important consideration for considering “platforms” for future COVID vaccinations.
It’s not hard to read between the lines here. Readers of #PopularRationalism already know the mRNA vaccines have proven to be worse than a dismal failure.
This is the CDC putting the word out that a second round of vaccine development is expected, and is about the closest we’ll ever see to the CDC admitting the vaccination program has flopped.
And it’s surprising to see the ACIP focusing on future “effectiveness.”
Clearly, if newly formulated vaccines are proposed, they will be a square one in terms of the regulatory stage of development, and we should be seeing data on efficacy — which is a measure of a vaccine’s ability to reduce transmission in a prospective randomized clinical trial — not effectiveness, which is measured using real-world data.